Literature DB >> 17851080

A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Severo Salvadori1, Claudio Trapella, Stella Fiorini, Lucia Negri, Roberta Lattanzi, Sharon D Bryant, Yunden Jinsmaa, Lawrence H Lazarus, Gianfranco Balboni.   

Abstract

Opioid compounds with mixed micro agonist/delta antagonist properties could be used as analgesics with low propensity to induce tolerance and dependence. Here we report the synthesis of a new designed multiple ligand deriving from the micro selective agonist endomorphin-2 and the delta selective antagonist pharmacophore Dmt-Tic. As predicted, the resulting bivalent ligand showed a micro agonist/delta antagonist profile deriving from the corresponding activities of each pharmacophore.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17851080      PMCID: PMC2084217          DOI: 10.1016/j.bmc.2007.08.047

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  35 in total

1.  Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2.

Authors:  Yanfeng Gao; Xin Liu; Jie Wei; Beibei Zhu; Qiang Chen; Rui Wang
Journal:  Bioorg Med Chem Lett       Date:  2005-04-01       Impact factor: 2.823

Review 2.  Designed multiple ligands. An emerging drug discovery paradigm.

Authors:  Richard Morphy; Zoran Rankovic
Journal:  J Med Chem       Date:  2005-10-20       Impact factor: 7.446

3.  A potent and selective endogenous agonist for the mu-opiate receptor.

Authors:  J E Zadina; L Hackler; L J Ge; A J Kastin
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

4.  The mu-opioid receptor is necessary for [D-Pen2,D-Pen5]enkephalin-induced analgesia.

Authors:  I Sora; M Funada; G R Uhl
Journal:  Eur J Pharmacol       Date:  1997-04-18       Impact factor: 4.432

5.  Interaction of deltorphin with opioid receptors: molecular determinants for affinity and selectivity.

Authors:  L H Lazarus; S Salvadori; M Attila; P Grieco; D M Bundy; W E Wilson; R Tomatis
Journal:  Peptides       Date:  1993 Jan-Feb       Impact factor: 3.750

6.  Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.

Authors:  Tingyou Li; Yoshio Fujita; Kimitaka Shiotani; Anna Miyazaki; Yuko Tsuda; Akihiro Ambo; Yusuke Sasaki; Yunden Jinsmaa; Ewa Marczak; Sharon D Bryant; Severo Salvadori; Lawrence H Lazarus; Yoshio Okada
Journal:  J Med Chem       Date:  2005-12-15       Impact factor: 7.446

7.  The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.

Authors:  P W Schiller; M E Fundytus; L Merovitz; G Weltrowska; T M Nguyen; C Lemieux; N N Chung; T J Coderre
Journal:  J Med Chem       Date:  1999-09-09       Impact factor: 7.446

8.  Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells.

Authors:  Yulong L Chen; P Y Law; Horace H Loh
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.

Authors:  S Salvadori; M Attila; G Balboni; C Bianchi; S D Bryant; O Crescenzi; R Guerrini; D Picone; T Tancredi; P A Temussi
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

View more
  7 in total

Review 1.  Engineering endomorphin drugs: state of the art.

Authors:  Lawrence H Lazarus; Yoshio Okada
Journal:  Expert Opin Ther Pat       Date:  2012-01-04       Impact factor: 6.674

Review 2.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

3.  Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show in Vitro Kappa and Mu Opioid Receptor Agonism.

Authors:  Deanna Montgomery; Jessica P Anand; Nicholas W Griggs; Thomas J Fernandez; Joshua G Hartman; Ashley A Sánchez-Santiago; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Neurosci       Date:  2019-07-01       Impact factor: 4.418

4.  Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic.

Authors:  Gianfranco Balboni; Severo Salvadori; Ewa D Marczak; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Xuemei Peng; Yu Gui Si; John L Neumeyer
Journal:  Eur J Med Chem       Date:  2010-12-08       Impact factor: 6.514

Review 5.  Bi- or multifunctional opioid peptide drugs.

Authors:  Peter W Schiller
Journal:  Life Sci       Date:  2009-03-11       Impact factor: 5.037

6.  Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.

Authors:  Gianfranco Balboni; Stella Fiorini; Anna Baldisserotto; Claudio Trapella; Yusuke Sasaki; Akihiro Ambo; Ewa D Marczak; Lawrence H Lazarus; Severo Salvadori
Journal:  J Med Chem       Date:  2008-08-05       Impact factor: 7.446

7.  Design, Synthesis and Functional Analysis of Cyclic Opioid Peptides with Dmt-Tic Pharmacophore.

Authors:  Arijit Sarkar; Anna Adamska-Bartlomiejczyk; Justyna Piekielna-Ciesielska; Karol Wtorek; Alicja Kluczyk; Attila Borics; Anna Janecka
Journal:  Molecules       Date:  2020-09-17       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.